We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Medpace (MEDP - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Medpace is one of 1020 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Medpace is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for MEDP's full-year earnings has moved 2.4% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, MEDP has returned 10.6% so far this year. At the same time, Medical stocks have lost an average of 4%. This means that Medpace is outperforming the sector as a whole this year.
Another stock in the Medical sector, Clover Health Investments, Corp. (CLOV - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 243.5%.
In Clover Health Investments, Corp.'s case, the consensus EPS estimate for the current year increased 7.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Medpace belongs to the Medical Services industry, a group that includes 59 individual companies and currently sits at #133 in the Zacks Industry Rank. This group has lost an average of 13.4% so far this year, so MEDP is performing better in this area.
In contrast, Clover Health Investments, Corp. falls under the Medical Info Systems industry. Currently, this industry has 42 stocks and is ranked #29. Since the beginning of the year, the industry has moved -17%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Medpace and Clover Health Investments, Corp. as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Medpace (MEDP - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Medpace is one of 1020 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Medpace is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for MEDP's full-year earnings has moved 2.4% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, MEDP has returned 10.6% so far this year. At the same time, Medical stocks have lost an average of 4%. This means that Medpace is outperforming the sector as a whole this year.
Another stock in the Medical sector, Clover Health Investments, Corp. (CLOV - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 243.5%.
In Clover Health Investments, Corp.'s case, the consensus EPS estimate for the current year increased 7.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Medpace belongs to the Medical Services industry, a group that includes 59 individual companies and currently sits at #133 in the Zacks Industry Rank. This group has lost an average of 13.4% so far this year, so MEDP is performing better in this area.
In contrast, Clover Health Investments, Corp. falls under the Medical Info Systems industry. Currently, this industry has 42 stocks and is ranked #29. Since the beginning of the year, the industry has moved -17%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Medpace and Clover Health Investments, Corp. as they could maintain their solid performance.